Pharmaceuticals, Biotechnology and Life Sciences
Ablynx will present additional data from the Phase IIb RA combination study of its anti-IL-6R Nanobody, vobarilizumab, at the Annual Scientific Meeting of the Canadian Rheumatology Association, being held from 8-11 February 2017 in Ottawa, Ontario (Canada).
Eli Lilly has welcomed Carolyn R. Bertozzi, Ph.D., as a new member, of its board, starting on February 10, 2017, joining two committees of the board.
Oxford BioTherapeutics has appointed Bernd Seizinger as Chairman, and and Jean-Pierre Bizzari, M.D. as a non-executive director, calling it a significant strengthening of its oncology focused board.
PrEP Biopharm’s study of its drug, earlier confirmed helpful for influenza and human rhinoviruse (HRV), has been undertaken to test its efficacy of the people with asthma, and check for different dosage, showed varying results.
Amryt’s non-executive director Cathal Friel will step down from the board the last day of March 2017, the orphan diseases focused pharmaceutical company said Thursday.
Boiron has signed an agreement with Laboratoires Arkopharma to take over Laboratoire Ferrier, a subsidiary of Laboratoires Arkopharma.
Tetraphase Pharmaceuticals Inc Chief Executive Guy Macdonald said annual sales of the company’s lead experimental antibiotic for serious bacterial infections could climb as high as $700 million if approved.
Sanofi and Regeneron will continue marketing, selling and manufacturing Praluent in the United States (U.S.) during their appeal on Amgen’s patent claims.
Bayer’s and Janssen R&D’s drug for cardiac situations has already met its primary goals in the early third phase of testing, the companies said today, which concludes the testing.
U.S. Food and Drug Administration (FDA)’s Center for Drug Evaluation and Research (CDER) does not plan to hold an Advisory Committee meeting with Portola Pharmaceuticals for New Drug Application (NDA) for betrixaban, Portola said on Wednesday.